Grey Wolf Therapeutics
Biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation
Grey Wolf Therapeutics has raised €87M across 2 funding rounds from 7 investors, most recently a Series B round in May 2024. Based in Oxford, UK; active in Healthtech. Data as of 28 Oct 2026.
Oxford, UKgreywolftherapeutics.com ↗
Total raised
€87M
€87,355,448
Funding rounds
2
Investors
7
distinct backers
Active since
2023-01
latest 2024-05
Funding by year
EUR raised per yearGrey Wolf Therapeutics — funding by year — interactive chart.
Data table
| Grey Wolf Therapeutics — funding by year | |
|---|---|
| 2023 | €45M |
| 2024 | €42M |
Signals
High confidenceRaise-next likelihood33
base rate 48% for Series B
- ▼ Past typical raise window
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-05-23 | Series B | €42M | Andera Partners,British Patient Capital,Canaan Partners,Earlybird Venture Capital,ICG’s Life Sciences,Oxford Science Enterprises+1 more | View deal → |
| 2023-01-26 | Series B | €45M | Andera Partners,British Patient Capital,Canaan Partners,Earlybird Venture Capital,Oxford Science Enterprises,Pfizer Ventures | View deal → |
Investors
7Related news
- Grey Wolf Therapeutics Closes $49M Series B Financingfinsmes.com · 2023-01
- eu-startups.com
Similar companies
same sector or countryGlobal coverage: FundingData